Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results that could bode well for migraine patients

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results Tuesday that could bode well for migraine patients. At the Fifth Congress of the European Academy of Neurology held in Oslo, Norway, Teva presented additional positive results from a Phase 3b exploratory study dubbed FOCUS that evaluated its migraine drug fremanezumab in adults who previously experienced inadequate responses to two to four classes of preventive treatments.

The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the TEVA is 2.70%. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. The Institutional ownership for the TEVA is 62.40%.

Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that TEVA. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 0.56%.

[finviz ticker=TEVA]

Institutional transactions is the amount of a Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the TEVA is -2.14%.

A Healthcare sector firm, Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock gained 1.18% on Tuesday and when day-trade ended the stock finally concluded at $9.43 and number of shares that changed hands during the day are 11.44 Million. The number of shares TEVA stock currently held by all its shareholders are 1077.65 and floated shares, the number of shares are available for trading in an open market on last trading day are 1047.71. The average volume of shares for 3 months is 17307.73 and TEVA stock value has moved between $7.99 – 26.19 in last one year.

The Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s latest earnings date is 8/1/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The valuable gross margin for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 43.10% and the profit margin is -19.70% and the stock has gained -38.85% in 2019 to date.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s monthly stock performance is 5.96%, the quarterly performance is -37.26%, the half year performance is calculated as -38.85%. The yearly performance of TEVA is -61.23%.

The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Teva Pharmaceutical Industries Limited (NYSE:TEVA) weekly volatility is measured as 3.61% and monthly volatility measured as 5.03%.

Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. TEVA return on assets is -5.60%, the return on equity (ROE) of the Teva Pharmaceutical Industries Limited (NYSE:TEVA) is -24.70%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and TEVA return on investment is -3.20%.

The price to sales ratio is 0.56, and price to book ratio is 0.70, price to cash per share ration is 5.15, price to free cash flow is 22.63.

Analysts mean target price for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is $14.73 while analysts mean recommendation is 2.90. The current share price indicates that stock is -63.67% away from its one year high and is moving 18.47% ahead of its 52-week low. TEVA’s distance from 20 day simple moving average is 6.83% and distance from 50-Day simple moving average is -16.10%.

Leave a Reply